Urine CXCL10 Monitoring Trial in Kidney Transplant

Phase 3Active Not RecruitingNCT03206801

University of Manitoba420 enrolled

Overview

This is a Phase II-III multi-center prospective randomized controlled clinical trial of incident adult renal transplant patients. The primary objective of this study is to determine if the early treatment of rejection, as detected by urinary CXCL10, will improve renal allograft outcomes.

This is a Phase II-III multi-center prospective randomized controlled clinical trial of incident adult renal transplant patients. Patients will be screened for eligibility (n≈485) and n≈420 will be enrolled and undergo post-transplant surveillance with urinary CXCL10. Two hundred and fifty patients deemed at high risk for rejection based on a confirmed elevated urine CXCL10 will undergo 1:1 randomization to the intervention and control arms, stratified by center. The total study duration is approximately 5 years; and there two main phases - screening and intervention. All eligible, enrolled patients will undergo the Screening Phase (n≈420). Routine urine CXCL10 screening will be done from 2 weeks - 9 months post-transplant. We have previously shown that urine CXCL10 is elevated in ischemia-reperfusion injury, so screening will commence at 2 weeks (+/- 4 days) to exclude this as a potential confounding factor (60). If patient develops a confirmed elevated urine CXCL10 level and is considered high risk for rejection, they will proceed to Randomization in the Intervention Phase, which can occur anytime between 2 weeks - 9 months post-transplant. Participants in the Intervention Arm will undergo renal biopsy to check for rejection. Biopsy-proven subclinical rejection will be treated per study protocol. Participants in the Control Arm will continue routine post-transplant surveillance with serum creatinine and proteinuria; serial urine samples will continue to be collected and analyzed (blinded), but not used to direct care. All randomized participants will undergo a 12-month study exit visit with protocol biopsy to determine primary, secondary and long-term outcomes. Enrolled patients with persistently low urine CXCL10 and low risk of rejection from 2 weeks - 9 months post-transplant will be considered Off-Study (not randomized). They will undergo a 12-month study exit visit (+/- 7 days) to determine secondary and long-term outcomes.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

SCREENING

Masking

SINGLE

Enrollment

420

Conditions

Kidney Transplant; Complications Rejection of Renal Transplant

Interventions

Kidney transplant biopsyPROCEDURE

Elevated urine CXCL10 will trigger a study biopsy in patients randomized to the intervention arm. Subclinical rejection will be treated per protocol.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Participants must be able to understand and provide written informed consent 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. All ethnic and gender groups will have equal access to the study 4. Incident adult (age ≥18) renal transplant patients with a living or deceased donor kidney transplant 5. Confirmed elevated urine CXCL10:Cr without a urinary tract infection or gross hematuria. Exclusion Criteria: 1. Primary non-function 2. Blood group (ABO) incompatible 3. Pre-transplant donor specific antibody (DSA) positive (MFI\>1000 OR positive flow crossmatch) 4. Human leukocyte (HLA) 0 HLA antigen D-related (DR) + 0 major HLA class 2 (DQ) mismatch 5. Presence of other transplanted organ or co-transplanted organ 6. Medical contraindication to biopsy or rejection treatment 7. Followed outside of investigational center 8. Participation in other interventional trials within 4-weeks post-transplant or anytime post-transplant till study end at 12-months 9. Intention to not use a maintenance immunosuppression regimen consisting of calcineurin inhibitor (CNI) and anti-proliferative agents 10. Any condition that, in the opinion of the investigator, would pose risk to the subject's safe participation, or interfere with their ability to comply with the study requirements, or may impact the quality of interpretation of the data.

Locations (9)

Royal Adelaide Hospital

Adelaide, South Australia, Australia

University of Calgary

Calgary, Alberta, Canada

University of Manitoba, Transplant Manitoba Adult Kidney Program

Winnipeg, Manitoba, Canada

Western University

London, Ontario, Canada

Outcomes

Primary Outcomes

Death-censored graft loss

Return to dialysis or re-transplant

Time frame: 2 weeks-12 months post-transplant

Clinical indication biopsy-proven acute rejection

Clinical rejection, Banff criteria

Time frame: 2 weeks-12 months post-transplant

De novo donor specific antibody development

De novo human leukocyte antibody (HLA) antibodies, donor specific

Time frame: 2 weeks-12 months post-transplant

Subclinical tubulitis

Subclinical rejection, Banff criteria

Time frame: 12-month study exit biopsy

Interstitial fibrosis and inflammation (IFTA + i)

IFTA + i, defined by Mayo criteria

Time frame: 12-month study exit biopsy

Secondary Outcomes

Renal allograft function

Change in eGFR (slope, ∆) and graft function (eGFR) (absolute, mL/min)

Time frame: 6, 12, 24 and 60 months post-transplant

Microvascular inflammation

Banff ptc, g, c4d, cg

Time frame: 12-month study exit biopsy

Development IFTA from implantation to 12-months

Banff ∆ ci, ct, cv

Time frame: 12-month study exit biopsy

Days from transplantation to clinical-biopsy proven rejection

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.